Enanta Pharmaceuticals Inc. has disclosed new fused heterobicyclic derivatives reported to be useful for the treatment of hepatitis B virus (HBV) and hepatitis D virus (HDV) infections.
Enanta Pharmaceuticals Inc. has disclosed 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17-β-HSD 13) inhibitors reported to be useful for diseases of the liver.
Enanta Pharmaceuticals Inc. has patented heterocyclic compounds potentially useful for the treatment of metapneumovirus (MPV), influenza and respiratory syncytial virus (RSV) infections.
Recent genome-wide association studies have elucidated a spliced variant (rs72613567:TA) in 17β-hydroxysteroid dehydrogenase 13 (HSD17B13) found to be associated with decreased risk of chronic liver disorders. The presence of this variant also correlates with delayed onset of autoimmune hepatitis in carriers.
Enanta Pharmaceuticals Inc. has synthesized spirocyclic compounds acting as 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.
Researchers from Enanta Pharmaceuticals Inc. presented preclinical data for the small molecule non-nucleoside respiratory syncytial virus (RSV) L-protein inhibitor, EDP-323, being developed for the treatment of RSV infection.
Enanta Pharmaceuticals Inc. has presented heterocyclic compounds reported to be useful for the treatment of respiratory syncytial virus (RSV) and metapneumovirus (MPV) infections.
Respiratory syncytial virus (RSV) continues to be a tough indication. Enanta Pharmaceuticals Inc.’s phase IIb study of otherwise healthy adults treated with EDP-938, an N-protein inhibitor, missed its primary endpoint of reduction in total symptom score compared to placebo. It also missed the study’s secondary antiviral endpoints.
Two companies, Hightide Therapeutics Inc. and Axcella Health Inc., posted positive data from recent liver disease studies while Enanta Pharmaceuticals Inc. missed its phase II liver study’s primary endpoint.